RT Journal Article
SR Electronic
T1 A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.16.19015024
DO 10.1101/2019.12.16.19015024
A1 Joske Ubels
A1 Pieter Sonneveld
A1 Martin H. van Vliet
A1 Jeroen de Ridder
YR 2019
UL http://medrxiv.org/content/early/2019/12/19/2019.12.16.19015024.abstract
AB Many cancer drugs only benefit a subset of the patients that receive them, but are often associated with serious side effects. Predictive classification methods that can identify which patients will benefit from a specific treatment are therefore of great clinical utility. We here introduce a novel machine learning method to identify predictive gene expression signatures, based on the idea that patients who received different treatments but exhibit similar expression profiles can be used to model response to the alternative treatment. We use this method to predict proteasome inhibitor benefit in Multiple Myeloma (MM). In a dataset of 910 MM patients we identify a 14-gene expression signature that can successfully predict benefit to the proteasome inhibitor bortezomib, with a hazard ratio of 0.47 (p = 0.04) in class ‘benefit’, while in class ‘no benefit’ the hazard ratio is 0.91 (p = 0.68). Importantly, we observe a similar classification performance (HR class benefit = 0.46, p = 0.04) in an independent patient cohort which was moreover measured on a different platform, demonstrating the robustness of the signature. Moreover, we find that the genes in the discovered signature are essential, as no equivalent signature can be found when they are excluded from the analysis. Multiple genes in the signature are linked to working mechanisms of proteasome inhibitors or MM disease progression. In conclusion, our method allows for identification of gene expression signatures that can aid in treatment decisions for MM patients and provide insight into the biological mechanism behind treatment benefit.Competing Interest StatementJoske Ubels and Martin H van Vliet are employed by SkylineDx. Jeroen de Ridder is co-founder of Cyclomics B.V. Pieter Sonneveld served on an advisory board to SkylineDx.Funding StatementJoske Ubels is supported by a Van Herk charity PhD fellowshipAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets supporting the conclusions of this article are available on GEO. Gene expression data from the HOVON-65/GMMG-HD4 study is available at GSE19784 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19784). Gene expression data from both Total Therapy 2 and Total Therapy 3 are available at GSE2658 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2658). 30 patients from the Total Therapy 3 study used in the manuscript are not included in the GSE2658 dataset, these can be found in ArrayExpress dataset E-TABM-1138 (https://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1138/). The PFS survival data for all three studies are available at https://github.com/jubels/GESTURE, linked to the GEO and ArrayExpress IDs. All gene expression and survival data for the CoMMpass study is available at research.themmrf.org https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19784 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2658 https://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1138/ https://research.themmrf.org